In Populo by Westreich, Daniel et al.
In populo
Daniel Westreich1, Brian W. Pence2, and Abigail Norris Turner1
1Department of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, North
Carolina, USA
2Department of Community and Family Medicine, Global Health Institute, and Center for Health
Policy, Duke University, Durham, North Carolina, USA
3Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Ohio
State University, Columbus, Ohio, USA
Abstract
While the Latin phrase in vitro and in vivo are well understood in the medical literature, neither term
accurately describes the science performed at the level of the population by epidemiologists and
others. In particular, results in a single organism can differ broadly from results in a population, for
reasons from random error to herd immunity. We suggest that in populo, meaning literally “in the
people”, can fill this gap in the literature, and urge its wide adoption.
We write this brief note to propose the adoption of a new term – in populo, meaning “in the
people” or “in the public”1 – to describe population-based health sciences research, and to
parallel the widely used terms in vitro and in vivo.
While in vitro (meaning literally “in glass”1) is generally taken to refer to science performed
outside of living organisms, in vivo (literally, “in live beings”1) refers to experiments done in
whole organisms. To these two mainstays, additional terms have been added over the years.
Ex vivo (literally, “out of live beings”1) typically refers to live cells (or organs2) isolated from
an organism,3 and is sometimes used interchangeably with in vitro.4 The Latinate (that is, not
proper Latin) in silico refers to experiments done only on computer, such as modeling or
simulation studies;5,6 the similar, Latinate, and little-used in papyro indicates that the study
has been performed on paper, as with a meta-analysis.7 Table 1 summarizes the extent of the
use of these terms in the medical literature.
None of these terms, however, correctly describes the population-level work of many public
health scientists. While clinical trials are often considered in vivo research, we propose that
population-based health research is not well-served by a term which does not distinguish
between a 5,000-subject observational study and a pharmacokinetics study with n=1.
Importantly, the inferences drawn from individual-level observations may not hold at the level
of the population. A given therapy may improve the clinical outcome in a given patient (an in
vivo finding), while in a clinical trial with low probability of confounding, that same therapy
may not significantly improve clinical outcomes across the full patient population (an in
populo finding). Individual effects may differ widely from population effects for a number of
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reasons, ranging from random error, to dynamic population-level phenomena such as herd
immunity.8
Examples in which in vivo and in populo effects differ are abundant in the medical and public
health literature. For example, while the smallpox vaccine is highly effective, it is not 100%
efficacious in vivo; nonetheless, use of the ring vaccination strategy in populo led to the
eradication of that disease in the general human population.9 Many other vaccines benefit from
herd immunity in similar ways. In contrast, the rgp120 candidate HIV vaccine produced a
promising antibody response in vivo during Phase I/II trials10-12 but failed to prevent HIV
acquisition in two large in populo Phase III trials.13,14
When does an in vivo study graduate to in populo status? At the extremes of sample size, there
are fairly clear lines: rgp120 trials published from 1994 and 2000 included 57 and 33 subjects,
10,11 while the two Phase III trials included 5403 and 2546 subjects, respectively.13,14 Less
clear is the 2003 study,12 which included 370 subjects: in vivo, or in populo? We would argue
that more important than sample size is that these studies are clearly measuring qualitatively
different kinds of effects. While the Phase II trial studied vaccine immunogenicity, the Phase
III trials studied vaccine efficacy for prevention of HIV infection. This distinction between
biological and clinical outcomes seems key, although usage in the medical literature will
doubtless refine these ideas further.
In populo provides a useful counterpoint to in vivo and in vitro, reminding us that scientific
and analytical issues differ widely between the study of a single individual and the study of a
thousand. Thus we believe that in populo can find a useful place in the medical and public
health literature, and urge its adoption by the public health and medical research community.
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Table 1
Use of selected Latin and Latinate terms in the medical literature
Term Meaning First use, PubMed 15 Total uses, PubMed 15
In vitro In glass 191116 962,506
In vivo In live beings 191817 482,751
Ex vivo Out of live beings 19642 27,253
In silico In computer simulation 199118 6,715
In papyro On paper None indexed 0
In populo In the population 2009 1‡
‡
This essay, excepting five citations with an author last name Populo.
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